[PDF] Top 20 The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
Has 10000 "The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis" found on our website. Below are the top 20 most common "The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis".
The effect of intramuscular interferon beta-1a on spinal cord volume in relapsing-remitting multiple sclerosis
... Baseline demographic and clinical data of the MS and normal control (NC) groups are summarized in Table 1. We retrospectively analyzed 16 consecutive patients with relapsing-remitting MS (RRMS) receiving ... See full document
8
Seasonal adherence to, and effectiveness of, subcutaneous interferon β-1a administered by RebiSmart® in patients with relapsing multiple sclerosis: results of the 1-year, observational GEPAT-SMART study
... and beta-1b) are among the first Disease Modifying Drugs (DMDs) that were approved for ...with Relapsing-Remitting Multiple Sclerosis (RRMS) in ... See full document
11
Profile of PEGylated interferon beta in the treatment of relapsing-remitting multiple sclerosis
... for relapsing-remitting multiple ...them, interferon (IFN) beta remains a valid treatment approach because of its good ben- efit/risk ...IFN beta is limited by uncomfortable side ... See full document
8
Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective?
... al: Intramuscular interferon beta-1a for disease progression in relapsing multiple ...The Multiple Sclerosis Collaborative Research Group ... See full document
6
Impact of adherence on subcutaneous interferon beta-1a effectiveness administered by Rebismart<sup>®</sup> in patients with multiple sclerosis
... Multiple sclerosis (MS) is a chronic, inflammatory, and degenerative disease of the central nervous system with a heterogeneous clinical ...to relapsing-remitting MS (RRMS) characterized by ... See full document
7
Pegylated versus non-pegylated interferon beta 1a in patients with relapsing-remitting multiple sclerosis: A cost-effectiveness analysis
... of interferon beta 1a has been approved by the United States Food and Drug Administration (USFDA) as a new treatment for patients with ...PEG-interferon beta 1a, it seems ... See full document
6
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing–remitting multiple sclerosis at year 1
... 1 effect of IFN β -1a 44 μ g SC tiw in prespecified subgroups of ...-1a: interferon beta-1a; MRI: magnetic resonance imaging; MS: multiple sclerosis; OR: odds ... See full document
9
Advances in the treatment of relapsing–remitting multiple sclerosis: the role of pegylated interferon β-1a
... IFNβ, interferon beta; M, macrophage; MMP, matrix metalloproteinase; MS, multiple sclerosis; PEG, polyethylene glycol; PEG-IFNβ, pegylated interferon β; TIMP-1, tissue inhibitor of ... See full document
14
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
... subcutaneous interferon beta-1a treatment was safe, and although many patients in the treatment arm dropped out, most patients tolerated methylprednisolone as an add-on to interferon ...on ... See full document
14
Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis
... peginterferon beta-1a in patients with RRMS ...of relapsing MS as defined by the McDonald criteria [25], an age of 18–65 years, a score of 0–5 on the Expanded Dis- ability Status Scale (EDSS [26]), ... See full document
11
PEGylated interferon beta-1a in the treatment of multiple sclerosis – an update
... for relapsing– remitting multiple sclerosis (MS) exhibits proven, but limited, efficacy and increased side effects due to the need of frequent application of the ...PEG-IFN ... See full document
8
Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis
... and interferon beta-1a treatment pointed out that an abnormal recruitment of the fronto-thalamic circuitry is associated with interferon-induced fatigue in MS patients ...in multiple ... See full document
6
Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis
... with intramuscular interferon b -1a in one of its Phase III trials and demonstrated greater ...subcutaneous interferon b -1a in three clinical ...with relapsing remitting ... See full document
9
The assessment for disinvestment of intramuscular interferon beta for relapsing-remitting multiple sclerosis in Brazil
... The first step undertaken in the disinvestment process was the analysis of the efficacy of the different available treatments, building on the Cochrane review [25]. Since the Cochrane review compared 15 ... See full document
13
Emerging oral immunomodulating agents – focus on teriflunomide for the treatment of multiple sclerosis
... in Multiple Sclerosis (ECTRIMS) meet- ing in ...with relapsing MS already on a stable dose of IFN- β ...β 1a – 30 μ g intra- muscularly once weekly or 22 μ g subcutaneously three times ...β ... See full document
14
Profile of oral laquinimod and its potential in the treatment of multiple sclerosis
... 44% (P = 0.0013) reduction in cumulative number of new T2 lesions, 51% (P , 0.0001) reduction in the mean cumu- lative number of gadolinium-enhancing lesions per scan from weeks 12 to 36, and a 51% (P = 0.0064) reduction ... See full document
8
The use of natalizumab for multiple sclerosis
... IFN beta-1a 30 µ g via intramuscular injection ...IFN beta-1a therapy ...IFN beta-1a alone, a 54% reduction in the relapse rate ...This effect was durable at 2 ... See full document
12
An Atypical Presentation of Multiple Sclerosis
... We demonstrated a possibility of Multiple Sclerosis presenting with severe headache and vomiting. MS exerts a considerable socioeconomic burden on society by affecting the adult in the prime of their ... See full document
5
Understanding and meeting injection device needs in multiple sclerosis: a survey of patient attitudes and practices
... A third of respondents reported that they relied on others (at least part of the time) to administer injections. The per- centage of patients who self-injected among those receiving medications for which an autoinjector ... See full document
8
The MRZ reaction in primary progressive multiple sclerosis
... Table 3 illustrates how inconsistent results of MRZR studies can appear if differences in definition (MRZR-2 vs. MRZR-1) are not considered. After clearly distin- guishing between MRZR-2 and MRZR-1, the MRZR results from ... See full document
8
Related subjects